ea0090oc7.5 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023
Marra Giusy
, Treppiedi Donatella
, Muro Genesio Di
, Mangili Federica
, Catalano Rosa
, Esposito Emanuela
, Nozza Emma
, Locatelli Marco
, Lania Andrea
, Sala Elisa
, Ferrante Emanuele
, Arosio Maura
, H. Burns Lindsay
, Mantovani Giovanna
, Peverelli Erika
The main target of pharmacological therapy for growth hormone (GH)-secreting pituitary tumors (GH-PitNET) is the somatostatin receptor type 2 (SST2). However, approximately half of patients treated with octreotide, an SST2 agonist, show a low response rate or are octreotide-resistant. Here we present mechanistic data that shows co-treatment with simufilam, a novel oral therapeutic candidate, enhances sensitivity to octreotide. We previously showed that the cytoskeleton protein...